Business Context and Reporting Period
This Form 6-K filing by XTL Biopharmaceuticals Ltd. covers the month of May 2026, with the report dated May 7, 2026. The filing primarily addresses the company's ongoing efforts to maintain its listing on The Nasdaq Stock Market after being notified of potential delisting due to "public shell" status under Nasdaq Listing Rule 5101.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed relates to a secured commitment for an investment of up to US$1,500,000 through a private placement, contingent upon the closing of the Psyga Transaction.
Material Changes and Corporate Developments
- Nasdaq Listing Decision: On May 4, 2026, the Nasdaq Hearings Panel granted the company an exception to continue its listing, reversing the initial delisting notice received in February 2026.
- Psyga Transaction: The company entered into a share purchase agreement to acquire all issued and outstanding share capital of Psyga Bio Ltd. on a fully diluted basis.
- Compliance Conditions: Continued listing is conditional on completing the Psyga Transaction and demonstrating compliance with all Nasdaq requirements by June 30, 2026.
- Stock Price Compliance: The company noted it has maintained a closing bid price in excess of $1 since completing a reverse stock split on March 25, 2026, addressing a previous violation of Listing Rule 5550(a)(2).
Guidance, Outlook, and Risks
Management anticipates closing the Psyga Transaction after shareholder approval, no later than June 29, 2026. The filing includes a cautionary note regarding forward-looking statements, highlighting significant risks that could prevent the transaction from closing or the company from regaining full compliance. Key risks include the failure to satisfy closing conditions, inability to secure necessary funding, integration challenges with Psyga, and the possibility that the Panel may reconsider the exception terms based on future events.
Investor Verification Checklist
- Verify the status of shareholder approval for the Psyga Transaction.
- Confirm the final closing date of the Psyga Transaction against the June 30, 2026 deadline.
- Monitor the company's ability to secure the full US$1,500,000 private placement commitment.
- Review the upcoming Form 20-F annual report for timely filing and full financial disclosure.
- Track any further communications from Nasdaq regarding the exception period or compliance status.